The standard treatment for newly-diagnosed multiple myeloma (NDMM) is autologous stem cell transplantation (ASCT). For this procedure, a patient's own healthy, blood-forming cells are collected. The patient then receives high-dose chemotherapy or radiation to kill the cancer cells. Then their healthy cells are returned to their body to recover. While ASCT is effective for many patients, it has significant side effects and may not be the best option for every patient with NDMM. In this research study, participants will receive one of two (2) study treatments: a new regimen of elranatamab plus daratumumab or a conventional regimen of ASCT plus lenalidomide and daratumumab. The delayed use of ASCT, as explored in this research study, is experimental and not standard-of-care.

We are conducting a study to see how money concerns can affect people with advanced cancer. The goal of this study is to see if monthly check-ins about money problems help ease financial worries for adults with advanced cancer who are getting treatment. If you or someone you know is dealing with money stress while having cancer, we'd like to hear from you. Your participation can help improve care for future patients.

We're testing a new blood test called Multi-Cancer Detection (MCD). This test looks for signs of many types of cancer. We want to learn if it can find cancer early when treatment might work better. Your participation could make a big difference. Thank you for considering joining us!

Do you have pancreatic cancer that is "locally advanced"? This means it can't be removed by surgery, but it hasn't spread elsewhere. Have you recently had chemotherapy, and your tumor has either shrunk or stopped growing? If so, you might be able to join a research study. The study looks at whether adding a high dose of radiation therapy can help people live longer or feel better compared to the usual treatment.

The purpose of Substudy 1 is to characterize the safety and tolerability of ABBV-453 in combination with other antimyeloma agents in subjects with Relapsed or Refractory (R/R) Multiple Myeloma (MM) and to determine the recommended Phase 2 doses (RP2D) of ABBV-453 in combination with daratumumab + dexamethasone (Dd) in subjects with R/R MM.

The goal of this Study is to provide prospective evidence of the frequency of skin discoloration in patients who have received the Magtrace® tracer for sentinel lymph node biopsy (SLNB) and to evaluate the impact that skin discoloration has on patients when it does occur, by using patient reported outcome measures such as questionnaires.

Do you speak Spanish or identify as Hispanic or Latino and have cancer? You can help improve cancer care by sharing your experience. We need patients to complete a one-time survey about your health, background, and cancer treatment. Your input is important and can help others receive better care. Participation involves only a one-time survey, with no required medical tests. ¿Es usted un adulto hispano, latino o de habla hispana con cáncer? Puede ayudar a mejorar la atención del cáncer al compartir su experiencia. Le pedimos a los pacientes que completen una encuesta una sola vez sobre su salud, antecedentes y atención médica durante o después del tratamiento. Su voz es importante y puede ayudar a que otros reciban mejor atención. La participación consiste únicamente en una encuesta, sin pruebas médicas obligatorias.

The purpose of this study is to learn how microbes in the uterus and gut (bacteria, viruses, fungi) and your own innate immune system (the first line of defense of the body) impacts how well certain treatments work for endometrial cancer. This is a hybrid decentralized study where some if not all assessments may be performed close to your home.

This research study aims to investigate the use of circulating tumor DNA (ctDNA) monitoring to detect early signs of cancer recurrence in patients with triple-negative breast cancer (TNBC) after standard treatment. TNBC is aggressive and has a higher risk of recurrence, often detected only after symptoms appear. This study will monitor ctDNA levels through blood samples collected during and after adjuvant therapy. If ctDNA is not detected, participants will continue monitoring. If ctDNA is detected, the study offers an investigational treatment, datopotamab deruxtecan (Dato-DXd), to address this potential recurrence risk. Participation in this study will help determine if ctDNA monitoring can improve the early detection of recurrence and potentially lead to better treatment strategies and outcomes for patients with TNBC in the future.

Do you have cancer that has spread to your bones (high-risk bone metastases)? Is your cancer not causing any pain, or asymptomatic? If so, you may be able to take part in a research study comparing the standard approach with the standard approach plus radiation therapy to see if it's better at lowering bone metastases-related complications.